Unprovoked venous thromboembolism: patient perspectives
Di Nicoletta Riva | 21 Luglio 2026 | 0
Ultima modifica: 3 Agosto 2026
The Dalì study Presented at the International Society on Thrombosis and Haemostasis 2026 Congress...
Aspirin for the Prevention of Venous Thromboembolism After Hip and Knee Arthroplasty?
Di Stefania Cavazza | 20 Luglio 2026 | 0
Ultima modifica: 3 Agosto 2026
Canadian investigators went beyond the EPCAT II trial (1) and presented the EPCAT III study at the Congress of the International Society on Thrombosis and Haemostasis (ISTH) 2026 in Paris. The double-blind randomized trial, simultaneously published in the New England Journal of Medicine, compared antithrombotic prophylaxis with aspirin (ASA) alone versus rivaroxaban followed by ASA after hip or knee arthroplasty (2).
Persistent positivity of Antiphospholipid Antibodies: results from the START2 Registry
Di Stefania Cavazza | 20 Luglio 2026 | 0
Ultima modifica: 3 Agosto 2026
Presented at the ISTH 2026 Congress in Paris and simultaneously published on Thrombosis Research, the results of the START2 observational study describe five hundred patients with persistently positive antiphospholipid antibodies (aPL) followed in major Italian Thrombosis Centers (1).
Prevention of Recurrent Superficial Venous Thrombosis: First Randomized Trial with Mesoglycan
Di Stefania Cavazza | 20 Luglio 2026 | 0
Ultima modifica: 3 Agosto 2026
The METRO study (MEsoglycan for the secondary prevention of superficial vein ThROmbosis) was presented at the ISTH 2026 Congress by Prof. Giuseppe Camporese. The study, simultaneously published in eClinicalMedicine (Lancet), evaluated one year of treatment with mesoglycan versus placebo after resolution of an acute episode of superficial venous thrombosis (SVT). The research documented an approximately 30% reduction in recurrent SVT compared with placebo during the year following treatment discontinuation. The Italian study also provided the first prospective data on the natural history of SVT, reporting a 39% recurrence rate at two years in the group that received no preventive therapy after resolution of the acute thrombotic episode (1). We discussed these findings with Prof. Camporese (video).
